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BACKGROUND. Alternative splicing of the osteopontin (opn, spp1) gene generates three
protein splicing isoforms (OPN-SI), designated as OPNa, OPNb, and OPNc, which have dem-
onstrated specific roles in different tumor models. This work aims to investigate the roles of
each OPN-SI in prostate cancer (PCa) progression by using in vivo and in vitro functional
assays.
METHODS. The expression levels of OPN-SI in prostate cell lines were analyzed by
qRT-PCR. PC-3 was stably transfected with expression vectors containing OPNa, OPNb,
and OPNc, as well as empty vector controls. PC-3 cells overexpressing each construct were
analyzed for in vivo tumor growth and in relation to different aspects mimicking tumor
progression, such as cell proliferation, migration, invasion, and soft agar colony formation.
RESULTS. OPN-SI are overexpressed in PCa as compared to non-tumoral prostate cell lines.
OPNc and OPNb overexpressing cells significantly activated enhanced xenograft tumor
growth and PC-3 proliferation, migration, invasion, and soft agar colony formation, as well
as the expression of MMP-2, MMP-9, and VEGF. These isoforms also support sustained pro-
liferative survival. We found that both OPNc and OPNb pro-tumorigenic roles are mainly
mediated through PI3K signaling. Inhibition of this pathway by using LY294002 specifically
inhibited tumor progression features evoked by OPNc and OPNb overexpression.
CONCLUSIONS. Our data provide evidence that both OPNc and OPNb splicing isoforms
promote distinct aspects of PCa progression by inducing PI3K signaling. These data give
support to strategies aiming to downregulate OPNc and OPNb expression as an approach to
inhibit PCa progression. Prostate # 2012 Wiley Periodicals, Inc.
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Prostate cancer (PCa) comprises a heterogeneous
group of tumors with a broad spectrum of pathological,
molecular features and clinical behaviors. This diversity
confounds the development of therapy strategies and
of specific biomarkers, especially due to differences in
genetic composition. An improved understanding of
the molecular basis of prostate carcinogenesis and
tumor progression could establish new PCa markers
and also help to identify new targets for improved
treatment options.
In PCa, previous studies suggest a role for increased
osteopontin (OPN, SPP1) tissue expression both in the
malignant transformation of prostate epithelial cells
and also as an important determinant of tumor pro-
gression and patient survival [1–5]. This glycophos-
phoprotein act as important autocrine and paracrine
signal that affect growth and behavior of prostate
carcinoma cells [2,3]. Besides, OPN has also been
described as an important marker for stage, grade,
and early tumor progression in PCa [6,7].
Variations in splicing enhance proteome diversity
and modulate cancer-associated proteins. OPN mRNA
is subject to alternative splicing, resulting in OPN
splicing isoforms (OPN-SI) that are shorter than full-
length OPN [8–11]. Cancer-specific splicing variants
potentially provide diagnostic, prognostic, and pre-
dictive biomarkers, in addition to potential targeted
therapies [12]. Osteopontin-a (OPNa) is the full-length
isoform, while osteopontin-b (OPNb) lacks exon 5
and osteopontin-c (OPNc) lacks exon 4 [9]. The roles
of OPN-SI have been demonstrated to be tumor spe-
cific, although the mechanisms controlling this are
currently unknown [8–11,13]. We recently published
the first report about OPN isoforms in PCa, by dem-
onstrating the expression pattern of each OPN-SI in
PCa and benign prostate hyperplasia (BPH) samples
[14]. We showed that OPNa, OPNb, and OPNc splice
variants are overexpressed in PCa in relation to BPH.
Besides, we observed that among these isoforms, the
OPNc variant was the most upregulated in PCa,
and outperformed the remaining isoforms and PSA
serum levels in PCa diagnostic accuracy. Additionaly,
immunohistochemistry analysis also demonstrated
OPNc protein upregulation in PCa samples as com-
pared to BPH tissues. OPNc protein was also strongly
stained in PCa tissues presenting high Gleason Score.
Although presenting this differential expression
pattern, data about the roles of each OPN-SI in PCa
progression are lacking, once all data regarding the
functional evaluation of OPN in PCa relates to the full
length isoform.
In the current study, we further identified OPN-SI
transcript overexpression in PCa in relation to non-
tumoral prostate cell lines. Based on this evidence
and on our previous data [14] of a potential role for
OPN-SI in PCa progression, we addressed the func-
tion of PCa-derived OPN-SI by examining the effect
of their ectopic overexpression in PC-3 cells. PC-3 cells
overexpressing each of the OPN-SI were evaluated for
features mimicking different steps of PCa tumor pro-
gression by in vivo and in vitro approaches. Our data
demonstrated by the first time that the overexpression
of OPNc and OPNb increases PC-3 cell growth,
sustained proliferative survival, migration, invasion,
anchorage-independence, and tumor formation in
vivo, suggesting a possible functional role for OPNc
and OPNb in PCa progression and survival. Addi-
tionally, we demonstrated herein that these tumor
promoting roles could be mediated through the acti-




We used three PCa cell lines: PC-3, DU-145, and
LNCaP (supplied from ATCC) and two non-tumoral
prostate cell lines, RWPE-1 and PrEC, which were
cultured in standard conditions. RWPE-1 and PrEC
cell line were a gift from Dr. Carlos Moreno (Emory
University, EUA). All cell lines were cultured in culture
medium (CM) supplemented with 10% fetal bovine
serum (FBS), 100 IU/ml penicillin and 100 mg/ml
streptomycin in a humidified environment containing
5% CO2 at 378C.
The open reading frame of OPN splice variants,
OPNa, OPNb, and OPNc were cloned into pCR3.1
mammalian expression vector as previously described
[9]. OPN-SI expression vectors were kindly provided
by Dr. George Weber (Cincinnati University) and
these DNA constructs were used for transfection into
PC3. Transfections were performed using Lipofecta-
mineTM 2000 (Invitrogen, CA). Expression plasmids
were transfected into PC-3 cells and the stably
expressing cell clones were selected with 800 mg/ml
of G418. Six OPN isoform overexpressing clones
(designated OPNa1, OPNa4, OPNb2, OPNb4, OPNc1,
and OPNc4) and one empty vector control clone
(empty vector) were selected.
QuantitativeReal-TimeRT-PCR(qRT-PCR)
RNA was extracted using the RNeasy kit (Qiagen).
cDNA synthesis was carried out using SuperScript II
First-Strand Synthesis System for RT-PCR using
oligo(dT) primer (Invitrogen) and 1 mg of total RNA.
Conditions for MMP-2 and MMP-9 PCR amplification
by qRT-PCR were 508C for 2 min, 948C for 5 min
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followed by 40 cycles of 948C for 30 sec, 588C for
30 sec, and 728C for 90 sec; 728C for 15 min and finally
a melting curve analysis (60–908C with a heating rate
of 0.28C and continuous fluorescence measurement).
Conditions for VEGF PCR amplification were 508C
for 2 min, 948C for 5 min followed by 40 cycles of
948C for 30 sec, 608C for 30 sec, and 728C for 90 sec;
728C for 15 min and finally a melting curve analysis
(60–908C with a heating rate of 0.28C and continuous
fluorescence measurement).
The amplification of fragments corresponding to
each OPN isoform, MMP-2, MMP-9, and VEGF was
performed using the following oligonucleotide pairs:
OPNa:50-ATC TCC TAG CCC CAC AGA AT-30
(forward) and 50-CAT CAG ACT GGT GAG AAT
CAT C-30 (reverse); OPNb: 50-CTC CTA GCC CCA
CAG ACC CT-30 (forward) and 50-TAT CAC CTC
GGC CAT CAT ATG-30 (reverse); OPNc: 50-CTG AGG
AAA AGC AGA ATG-30 (forward) and 50-AAT GGA
GTC CTG GCT GT-30 (reverse); MMP-2: 50-AAA ATG
GAT CCT GGC TTC CC-30 (forward) and 50-TAG
CCA GTC GGA TTT GAT GC-30 (reverse); MMP-9:
50-TGA CAG CGA CAA GAA GTG-30 (forward) and
50-CAG TGA AGC GGT ACA TAG G-30 (reverse);
VEGF: 50-CTT GCC TTG CTG CTC TAC C-30
(forward) and 50-CAC ACA GGA TGG CTT GAA
G-30 (reverse). GAPDH was amplified with primers
50- TGA CCC CTT CAT TGA CCT CA -30 (forward)
and 50-AGT CCT TCC ACG ATA CCA AA-30 (reverse),
and Actin was amplified with primers 50-TGA CCC
AGA TCA TGT TTG AGA-30 (forward) and 50-ACT
CCA TGC CCA GGAAGGA -30 (reverse), which served
as an internal control to normalize expression data and
to verify integrity of the cDNA. All qRT-PCR reactions
were conducted using the SYBR Green (Applied
Biosystems). Relative gene expression of the target
gene was calculated by using the DDCT method.
Ki-67 Staining
The expression of Ki-67 was accomplished via
immunohistochemical techniques on serial paraffin
sections of xenograft tumors overexpressing each
OPN-SI and controls. Tumors were fixed in 4% para-
formaldehyde in 0.1 M phosphate buffer. Samples
were paraffin embedded and tissue sections were
processed using standard protocols. The mouse
monoclonal Ki-67 antibody (clone MIB-1, Dako) was
used at a dilution of 1:50. The next incubation step
employed the streptavidin-biotin-peroxidase complex
(LSAB, Dako) and color development was obtained
with diaminobenzidine solution (Kit DAB, Dako). The
positive immunoreactions were manually counted
using a 40! magnification at Olympus BH-2 micro-
scope coupled to a digital camera.
CellProliferation,Death,Migration,Invasion,andSoft
AgarGrowthAssays
Cell proliferation was analyzed by crystal violet.
Cell death analyses were conducted by using trypan
blue exclusion assays. For the analysis by crystal
violet and Trypan blue, wild-type PC-3, PC-3 cells
transfected either with OPNa, OPNb or OPNc plas-
mid constructs, or pCR3.1 empty vector were plated
in triplicate in 24-well microtiter plates. For these
assays, 5 ! 104 cells were plated per well. For crystal
violet incorporation assays, cells were washed twice
with PBS and fixed in glutharaldeyde for 10 min,
followed by staining with 0.1% crystal violet and sol-
ubilization with 0.2% Triton X-100. Microtiter plates
were read on a spectrophotometer at 550 nm. Viable
and non-viable cells were counted using a Neubauer’s
chamber. Total number of cells/well for each cell
clone group was calculated and plotted against each
time point. Cell proliferation assays for OPNc deple-
tion using anti-OPNc antibody were evaluated either
in the absence or in the presence of anti-OPNc IgY
antibody (Gallus Immunotech), added every other
day at 4 mg/ml. This antibody was produced by im-
munizing a chicken with a peptide representing the
splice junction of osteopontin-c (Ac-SEEKQNAVSC-
COOH). Specific binding to OPNc has been has been
demonstrated by the providers. Proliferation assays
were also performed using non-specific goat IgG and
chicken IgY antibodies (Gallus Immunotech) as im-
munoglobulin negative controls (4 mg/ml). In order
to test whether secreted OPN isoforms were perform-
ing the observed cell behavior, wild type PC-3 and
RWPE-1 cells were incubated with conditioned
media (CM) obtained from PC-3 cells transfected with
OPNa, OPNb, OPNc or empty vector, and cell prolif-
eration was measured by crystal violet incorporation.
These assays were performed in serum-free condi-
tions, in order to eliminate skewing of the results by
cell activation promoted by growth factors. Forty two
hours before starting the experiment, cells were cul-
tured in 0.2% FBS in order to synchronize cells on cell
cycle. In order to prepare CM, cell number was nor-
malized by plating the same cell amount of cells in
each assayed culture plate for individual OPN-SI
overexpressing clone.
Cell migration assays were evaluated by in vitro
wound closure and transwell assays, as described by
others [15]. Wild-type PC-3 or PC-3 cells transfected
with either OPNa, OPNb, OPNc, or empty vector were
grown in six-well microtiter plates to near-confluent
level in RPMI medium containing 20% FBS. Mitomycin
C (5 mg/ml; Sigma) was added to inhibit cell prolifer-
ation, and the cells were incubated for additional
3 hr. Multiple uniform and constant streaks were
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made on the monolayer culture with 10 ml pipette
tips. Plate dishes were immediately washed with PBS
to remove detached cells. Cell migration was moni-
tored for 72 hr, and pictures were taken at 0, 18, 24, 48,
and 72 hr time points with a digital camera attached to
an inverted Nikon phase contrast microscope.
To determine the effect of OPN isoforms on the
invasion potential of PC-3 cells, transwell invasion in
vitro assays were performed as reported [16]. Cell cul-
ture inserts (24-well, pore size 8 mm; BD Biosciences)
were seeded with 25,000 wild-type PC-3 cells, PC-3
cells transfected either with OPNa, OPNb or OPNc
plasmid constructs, or pCR3.1 empty vector in 500 ml
of medium with 0.1% FBS. Pre-coated inserts with
growth factor reduced Matrigel (40 ml, 1 mg/ml; BD
Biosciences) were used. As chemotactic agent added
at the lower chamber, 750 ml of CM containing 20%
FBSs has been used. After 48 hr, non-invading cells
were wiped from the upper side of the membrane
and cells on the lower side were fixed in glutharal-
deyde followed by staining with 0.1% crystal violet.
The lower side of the filter was photographed by
using a phase-contrast microscope at 10-fold magnifi-
cation and the number of cells was manually counted.
Each individual experiment had triplicate inserts and
six microscopic fields were counted per insert.
Anchorage independent growth was analyzed in
soft agar medium. Six-well plates were coated with
1.2% agarose-supplemented growth medium to resist
cell adhesion. PC-3 wild-type or PC-3 cells transfected
with either OPNa, OPNb, OPNc, or empty vector
were then trypsinized, and 5 ! 102 cells were resus-
pended in 3 ml of growth medium containing 0.6%
agarose. After being plated, colonies were allowed to
grow for 4 weeks. Representative colonies were
visualized by both phase contrast microscopy and the
total number of colonies was determined.
PreparationofCell Lysatesand Immunoblot for
DetectingOPNIsoforms
Cells were harvested and rinsed twice with PBS.
Cell extracts were prepared using cell lysis solution
containing SDS 1% and phosphatase and protease
inhibitors. Cells were scraped and total protein
extract was purified using 20 mm mini spin Receiver
Columns (Macherey-Nagel) by centrifuging 1,400 rpm
for 1 min and then cell extracts collected. Total
protein concentration was measured using the BCA
assay kit (BioRad), according to the manufacturer’s
instructions. Immunoblot assays for detecting protein
isoforms were performed using 25 mg of purified
protein extracts, which were subjected to a 7.5% SDS/
PAGE and the resolved proteins were transferred
electrophoretically to PVDF (Millipore) membranes.
Membrane was blocked for 1 hr using 5% non-fat dry
milk diluted in Tris buffered saline (5%/TBS). Then,
membranes were incubated O/N with the human
anti-OPNc primary antibody (R & D systems) diluted
1:500 in 5%/TBS. After three washes for 10 min in
TBS buffer, membranes were incubated for 1 hr with
the anti-goat IgG-HRP secondary antibody. Chemilu-
minescence detection was performed using ECL
PLUS (Amersham Biosciences) in accordance with the
manufacturer’s instructions. As positive controls for
staining the three OPN isoforms with anti-OPNc anti-
body, we used whole cell extracts from MDA-MB-435




LY294002, a PI3K inhibitor, was obtained from Cell
Signaling Technology (Maryland). Untransfected
PC-3 cells and those overexpressing either OPN-SI
or empty vector control were cultured as described
above for cell proliferation, migration, and soft agar
colony assays and then treated with 50 mM of LY294002.
Immunoblot was performed using 50 mg of protein
extracts. Cells were harvested and rinsed twice with
PBS. Cell extracts were prepared with Cell Lysis Buffer
(Cell Signaling Technology), sonicated and cleared by
centrifugation at 15.000g. Total protein concentration
was measured using the BCA assay kit (BioRad),
according to the manufacturer’s instructions. PI3-
Kinase activation was analyzed by the levels of Akt
Ser473 phosphorylation. Membranes were incubated
with anti-total Akt and anti-phospho-Akt antibodies
(Cell Signaling Technology). The horseradish peroxi-
dase (HRP)-conjugated anti-rabbit IgG (Pierce, Rock-
ford, IL) were diluted 1:1,000 in PBST containing 5%
bovine serum albumin. Chemiluminescence detection
(Amersham Biosciences) was performed in accor-
dance with the manufacturer’s instructions.
InvivoTumorigenicityofOPN-SITransfectants
For the analysis of tumor progression in vivo we
used 6 weeks athymic BALB/cnude/nude mice. Mice
were injected subcutaneously (s.c.) into the left flank
with 5 ! 106 of PC-3 cell clones. Tumor volumes (V)
were analyzed every 2 days using the following
formula: V (mm3) " width ! length2 ! 0.52. A total
of 25 mice were randomly assigned to five groups
(five mice/group) corresponding to five transfectant
clones. Pictures were taken 24 days after injection.
Data andStatisticalAnalysis
All results are presented as mean # standard error
of at least three independent experiments. For in vitro
and in vivo data assays, statistical comparisons
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among groups were performed by the Student’s t-test
or ANOVA. P < 0.05 was considered significant.




We previously demonstrated that all OPN-SI are
overexpressed in PCa in relation to BPH samples and
that among these isoforms, OPNc was the most upre-
gulated in PCa samples. Additionally, we also dem-
onstrated that OPNc protein is overexpressed in high
Gleason Score (GS) tumor samples, as compared to
low GS samples [14]. To further validate these data
and compare OPN-SI expression profiling between
tumor and non-tumoral prostate samples, we used
herein OPN-SI specific oligonucleotides and qRT-PCR
to evaluate the expression level of these three splice
variants in prostate tumoral and non-tumoral cell
lines (Fig. 1A). We found that the three OPN-SI are
overexpressed in PCa cell lines, as compared to
non-tumoral samples. These data, in association with
our previous results [14], indicated that OPN-SI ex-
pression levels could be involved in PCa progression.
Based on these data, we then assessed the functional
significance of elevated OPN-SI expression during the
development of PCa by investigating whether the
stable overexpression of each OPN-SI in a human PCa
cell line could alter tumor growth in vivo and in vitro.
PC-3 cell line was stably transfected with expres-
sion plasmids containing the three OPN-SI. The anal-
ysis of isolated clones demonstrated that each OPN-SI
overexpression clone present higher mRNA levels of
the corresponding isoform in relation their endogenous
levels in empty vector transfected cells (Supplementary
Fig. 1A). This was further demonstrated at the protein
level (Fig. 1B). Immunoblot analysis of total protein
Fig. 1. OPN-SI are overexpressedinPCa andsupport tumorgrowth.OPN-SI expression levelswere analyzedbyqRT-PCRandwererepre-
sented by fold activation in relation to the sample presenting the lowest expressing levels.GAPDHwas used as a normalization control.A:
OPN-SImRNAexpression levels was analyzed in differentprostate cell lines.Results are representative of three independent experiments.
Horizontal bars represent standard deviations (S.D.).B: Immunoblot analysis using the human anti-OPNantibody and total protein extracts
from OPN-SI overexpression clones demonstrating the overexpression of OPNc (around 55 KDa), OPNb (around 60 KDa), and OPNa
(around 72 KDa) protein isoforms in each corresponding overexpression clone, respectively.OPN-SI molecular weights presents variability
according to post-translational modifications which are cell type dependent. Recombinant OPN and MDA-MB-435 total protein extracts
wereused as positive controls forOPN-SI detection and image on therightdemonstrates theX-ray filmexposed in a shorter time to better
demonstrate thebands corresponding to the three isoforms.C: PC-3 transfected cellswith eitherOPNa,OPNb orOPNc, or empty vector
control and proliferation kinetics analysis was evaluated by crystal violet staining. $P < 0.05 versus empty vector control clone.D: Tumor
growth rate of mice s.c implanted with OPN-SI overexpression cells and empty vector controls. PC3 non-transfected cells were also
implanted.$P < 0.05versusempty vectorcells.
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extracts from each OPN-SI isolated clone was probed
with a human anti-OPN antibody (R & D systems),
which recognizes three OPN isoforms. This antibody
recognizes predominantly OPNc (around 55 KDa),
OPNb (around 60 KDa), and OPNa (around 72 KDa)
isoforms on OPNc, OPNb, and OPNa overexpression
clones, respectively. These data demonstrated that
each overexpression clone present higher levels of
the corresponding protein OPN splicing isoform
(Fig. 1B). We firstly asked whether the proliferation
rates of PC-3 cells overexpressing OPNa, OPNb, and
OPNc were altered as compared to an empty vector
control clone. As shown in Figure 1C, OPNc overex-
pressing cells significantly activated proliferation
rates as compared to OPNa and empty vector control
clone in the range of 4–48 hr of cell culture (P < 0.05).
OPNb also stimulated PC-3 cell proliferation, however,
presenting no statistical significance (P " 0.07), as
compared to controls. Similar results were obtained
when analyzing proliferation rates by trypan blue
assays (Supplementary Fig. 2A). The same prolifera-
tion behavior was observed when testing stably
expressing clones presenting different OPN isoform
expression levels, as demonstrated on Supplementary
Fig. 2B–D. To further assess the functional signifi-
cance of elevated expression of OPN-SI during the
development of PCa, we then investigated whether
stable overexpression of each OPN-SI in PC-3 cell line
could alter the tumor growth in vivo. Tumors overex-
pressing OPNc, and to a lesser extent OPNb, grew
faster and produced tumors with higher volume as
compared to controls (Fig. 1D and Supplementary
Fig. 3). Implantation of cells overexpressing OPNc
resulted in extremely rapid tumor growth and forma-
tion of larger (%500 mm3) tumors between 17 and
19 days after s.c. injection. In contrast, tumors resulting
from OPNa or empty vector overexpressing clones
were of comparable size (<200 mm3) to those generated
with empty vector control cells. Taken together, these
results indicated that overexpression of OPNc and
OPNb are able to enhance xenograft prostate tumor
growth rates, suggesting that these isoforms acceler-
ate tumor progression.
Tissue sections from xenografts expressing the three
OPN-SI constructs were stained for Ki-67 to assess pro-
liferation. As shown in Figure 2A,B, the percentage of
Ki-67 positive nuclei in OPNc and OPNb overexpress-
ing tumors was 3.5 and 2.5-fold higher, as compared
to cells overexpressing OPNa and empty vector con-
trol, respectively. Ki-67 staining, in addition to cell
proliferation in vitro assays (Fig. 1C), indicated that
OPNc and OPNb overexpression were associated
Fig. 2. OPNc and OPNb activate tumor formation by inducing proliferation. Tumors formed by each OPN-SI PC-3 overexpressing
cells, as well as empty vector were analyzed for Ki-67 positive staining.A: Representative images of xenograft tumor spots showing Ki-67
expression as determined by nuclear staining, characterized by a dark brown reaction in the nucleus of tumor cells. 10! objectives on an
Olympus BH-2microscopewith the inset showing a 40!magnified viewof the same field.B: Quantification of immunohistochemical Ki-67
positivenuclei stainingas testedin (A).
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with increased PCa tumor growth. Real time PCR
analysis of total RNA obtained from xenograft tumors
resulting from OPNa, OPNb, and OPNc overexpres-
sion clones demonstrated that these tumor tissues
maintain each OPN-SI overexpression as compared
to tumors formed by empty vector transfected cells
(Supplementary Fig. 1B).
To further explore the role of each tumor derived
OPN-SI on the regulation of downstream molecules
involved on PCa tumor progression, we examined
whether tumor xenografts overexpressing OPN-SI
could induce MMP-2, MMP-9, and VEGF mRNA
expression. In PCa, a functional interplay and an
increased expression of these gene products is associ-
ated with invasive and metastatic potential. As shown
in Figure 3A–C, the expression levels of these
transcripts were up-regulated in OPNc and OPNb
overexpressing xenografts, as compared to those tumors
resulting from empty vector control (P < 0.01).
We then explored the functional mechanisms by
which OPN variants promote tumor growth. In order
to achieve this objective, we examined the biological
effects of OPN-SI overexpression in PC-3 cells under




In serum-starving conditions, cells overexpressing
OPNc and to a lesser extent, OPNb, can significantly
enhance cell proliferation (Fig. 4A). These results
suggest that OPNc and OPNb modulates the growth
of PCa cells independently of growth factors, typical
Fig. 3. MMPs and VEGF are overexpressed in PCa cells overexpressing OPNb and OPNc isoforms.A^C: Induction of MMP2 (A), MMP9
(B), andVEGF(C)mRNAexpressioninxenograft tumors formedbycells overexpressing the threeOPN-SI, as comparedto tumors formedby
PC3cells transfectedwith empty vectorcontrols.D^E: InductionofMMP2 (D),MMP9 (E), andVEGF (F)mRNAexpression in PC3cells over-
expressing the threeOPN-SI as compared to PC3 cells transfectedwith empty vector controls.Total RNA fromcells overexpressingOPNa,
OPNb, OPNc, and empty vector control was prepared to conduct quantitative real-time PCR (qRT-PCR) analysis using glyceraldehyde
3-phosphate dehydrogenase (GAPDH) or actin as internal controls. D^E: The amount of targets was analyzed using the comparative CT
method, where the threshold cycle (CT) values of each target sequence are givenby the 2_DDCT formula.Wepresent the data as log n-fold
change ingene expressionnormalized to the endogenousreferencegenes (GAPDHor actin) relative to the expressionofcells overexpressing
empty vectorcontrol.$P < 0.002.
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features of oncoproteins [17]. We then hypothesized
that the higher proliferation rates observed for OPNc
and OPNb overexpressing clones could be explained
by induction of cell death promoted by OPNa
overexpression. All three OPN-SI cell clones pre-
sented similar proportions of cell death, as shown by
exclusion of trypan blue analysis (data not shown).
These results further evidence the potential role of
OPNc and OPNb on favoring PCa cell proliferation
and survival, which is not associated with stimulated
cell death promoted by OPNa or control cells.
We also evaluated proliferation-kinetics of untrans-
fected PC-3 and RWPE-1 cells in the presence of con-
ditioned CM produced by each OPN-SI and empty
vector overexpressing cell lines (Fig. 4B,C). We found
that untransfected PC-3 cells cultured in OPNc-CM
and OPNb-CM displayed higher proliferation rates as
compared to controls. Of note, OPNc-CM, but not
OPNb-CM, stimulated the proliferation of RWPE-1
non-tumoral prostate epithelial cells (Fig. 4C). These
changes in PC-3 cell proliferation indicates that cell
growth were directly dependent on the secreted OPNc
protein, as the addition of a polyclonal anti-OPNc anti-
body, but not control anti-rabbit goat IgG immuno-
globulin, significantly suppressed proliferation rates
promoted by PC-3 overexpressing OPNc (Supple-
mentary Fig. 4A). Similar results were obtained when
performing these assays using an IgY non-specific
antibody as a negative control (data not shown).
Accordingly, these cells also presented an increase in
cell death, providing additional evidence for a surviv-
al effect for secreted OPNc in this prostate tumor cell
line (Supplementary Fig. 4B). The same effect was not
observed when anti-OPNc antibody was added to
OPNa overexpression clones (Supplementary Fig. 4C,D).
When the same procedure was performed on wild
type PC3 non-transfected cells, although presenting
no significant effect on cell proliferation, anti-OPNc
antibody increased cell death rates in these cells, indi-
cating that even basal OPNc levels in PC3 cells could
potentially also exert pro-survival roles (Supplemen-
tary Fig. 4E,F). These data indicated that this antibody
could specifically inhibit the effect of OPNc protein
isoform on cell proliferation and survival. Altogether,
these data indicated that secreted OPNc, in addition
to enhancing proliferation of PCa cells, also stimulates
proliferation of normal prostate epithelial cells, further
suggesting a role of this isoform in prostate tumori-
genesis and cell survival. Conversely, the OPNb iso-
form likely exerts its main effects on cell proliferation
at later stages of PCa progression. A serial dilution
analysis of OPNc and OPNb-CM promoted a propor-
tional decrease on PC3 cell proliferation (Supplemen-
tary Fig. 5A,C). On the other hand, OPNb-CM serial
dilution analysis only promoted a proportional decrease
on PC3 cell proliferation (Supplementary Fig. 5B).
On RWPE1 cells, proliferation rates were maintained,
even according to OPNb CM serial dilution analysis
(Supplementary Fig. 5D).
Fig. 4. OPNc and OPNb stimulate cell proliferation under serum
starving conditions by stimulating cell survival.A: Cells were grown
in 0.2% FBS and cell numberswere countedby crystal violet staining
at 96 hr after plating. O.D., optical density measured at 550 nm.
$P < 0.0001versusempty vectorcontrolclone.Allresults arerepre-
sentative of at least three independent experiments. PC-3 (B) and
RWPE-1 (C) non-transfected cellswere assayed for cell proliferation
ratesbycrystalviolet stainingafterincubationwithconditionedmedi-
um (CM) secreted from OPN-SI and empty vector overexpressing
cells.Legend on the right indicate fromwhich cell clones theCMwas
obtained. Results are representative of at least three independent
experiments.O.D., opticaldensityat 550 nm.The standarddeviations






We then elucidated whether OPN-SI overexpressed
in PC-3 cells are able to induce altered phenotypes
associated with additional processes favoring tumor
progression, such as migration, invasion, and anchor-
age independent cell growth.
PC-3 cells overexpressing OPN-SI or empty vector
were subjected to an in vitro wound closure migration
assay (Fig. 5A). Migration of OPNc and OPNb express-
ing cells were enhanced as compared to OPNa and
empty vector-expressing cells. Eighteen hours after
the scratch assay was initiated, OPNc and OPNb en-
hanced PC-3 cell motility into the wound. After 24 hr,
OPNc and OPNb overexpressing cells completely
closed the wound edges (data not shown).
OPNc and OPNb overexpression also stimulated
PC-3 invasion capacity by at least 5.0-fold and 2.5-
fold (P < 0.0001), as compared to cells overexpressing
OPNa and empty vector control (Fig. 5B). These results
suggest that OPNc and OPNb isoforms increased cell
migration and invasion of PC-3 cells in vitro.
Similarly to in vivo assays (Fig. 3A–C), there was a
significant increase in MMP-2, MMP-9, and VEGF
mRNA levels (P < 0.01) in PC-3 cells overexpressing
OPNc and OPNb, as compared to OPNa and empty
vector overexpressing clones (Fig. 3D–F). These
results indicated that the upregulation of these tran-
scripts could be one of the molecular mechanisms by
which these OPN variants can activate PC-3 cell mi-
gration and invasion capacity. OPNc-CM and OPNb-
CM also significantly activated PC-3 cell migration
and invasion (data not shown), reinforcing the notion
that the secreted isoforms of these OPN variants acts
as stimulatory factors for PC-3 cell proliferation, mi-
gration, invasion, and metastatic potential.
To examine whether OPN-SI overexpression also
alters the ability for anchorage-independent growth
as a measure for tumorigenic potential, soft agar
assays were performed. OPNc and OPNb overex-
pressing PC-3 cells significantly increased the number
of colonies formed, while OPNa isoform promoted no
significant effects (Fig. 5C). The three OPN-SI overex-
pression clones also promoted an increase in the size
of colonies formed, although OPNc and OPNb dis-
played a more pronounced effect (data not shown).
These data suggest that OPNc and OPNb can act as
activating factors to enhance anchorage independent




During PCa progression, tumor cells undergo
molecular alterations that lead to the acquisition of
uncontrolled growth properties. One such set of mo-
lecular alterations may be mediated by the PI3K-Akt
signaling pathway [18]. To explore the molecular
mechanisms by which OPN-SI mediate their effects
on PCa progression, we examined if the overexpres-
sion of each OPN-SI would modulate PI3K activity
and Akt phosphorylation (Ser473).
As shown in Figure 6A, an increased phosphoryla-
tion level on Ser473 was readily detected in protein
extracts of OPNc and OPNb overexpression cells
(2.1-fold and 1.46-fold increase, respectively), but not
in the vector-controls or OPNa overexpressing cells.
Differential ERK 1/2 hyperphosphorylation was not
observed among cell extracts overexpressing all OPN-
SI (data not shown). The activation of PC-3 cell prolif-
eration, migration and soft agar colony formation me-
diated by OPNc and OPNb overexpression were
significantly inhibited when these cells were treated
with LY294002 (Fig. 6B–D). PC-3 cells overexpressing
OPNc and OPNb could better overcome the effects
of LY29400 on inhibiting the number of soft agar
Fig. 5. OPNc and OPNb stimulate prometastatic processes in
PCa cells. Cell clones of OPN-SI and empty vector control cells
were analyzed for cell migration (A), invasion (B), and anchorage
independent growth (C). A: Phase-contrast micrographs photo-
graphswere takenat0and18 hr afterclones subjectedtomigration
by wound closure assays are shown. Samples were tested in
triplicates.B: Invadingcells testedby transwellinvasionassayswere
stained with crystal violet and the number of cells manually
counted. Data are reported as average of number of invading
cells # S.D. of three independent experiments. $P < 0.001. C:
Quantification of the number of PC-3 cell colonies grown in
semisolidagarosemediumtransfectedwithdifferentconstructs, as
indicated.Results are representative of at least three independent
experiments.$P < 0.01vesrsusempty vectorcells.
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colonies formed (Fig. 6D). These results indicate that
PI3K signaling is mediating tumor progression fea-
tures evoked by OPNc and OPNb overexpression.
DISCUSSION
Current data debate that OPN splice variants pres-
ent different tumor and tissue specific roles. While in
some tumor models an individual OPN-SI behaves as
a tumor stimulating factor, in other tumor contexts
the same variant presents just the opposite effect,
acting individually or in concert with the remaining
isoforms to modulate tumor progression [8–11,13].
Although total OPN has been a key biomarker for
detecting PCa progression, no reports until now have
described the roles of each OPN-SI in prostate
tumorigenesis [4–7]. Herein, we attempted to charac-
terize the involvement of each OPN-SI as an impor-
tant approach to understand some of the aberrant and
deregulated genetic control in PCa.
We previously demonstrated that OPN-SI are over-
expressed in PCa tissues in relation to BPH samples
and that OPNc protein was up-regulated in high glea-
son score tumor samples [14]. Data provided herein
reinforced OPN-SI transcript overexpression in PCa
cell lines as compared to non-tumoral ones. Based on
this, we then hypothesized whether this OPN-SI over-
expression in PCa could play important role in PCa
progression.
We found that cells overexpressing OPNc and
OPNb, but not the OPNa splice variant, are able to
enhance PCa tumor growth in vivo, mainly mediated
Fig. 6. PI3K/Akt signaling pathway mediate ONPc and OPNb roles on activating tumor progression features.A: Total Akt and p-Akt
(60 KDa) levels in PC-3 cells overexpressingOPN-SI andempty vectorcontrolweremeasuredbyimmunoblotusing their specific antibodies.
Non-phospho Aktwas used as a loading control. Fold changes were calculated based on densitometric quantification.B: Growth curves of
PC-3 overexpressing cell clonesOPNc,OPNb,OPNa, andempty vectors culturedwith or without LY294002 areplotted, as indicated at the
legend on the right. $P < 0.05 vesrsus empty vector control clone.C PC-3 cells overexpressing each OPN-SI, as compared to empty
vector control were evaluated for cells migration capacity by transwell assays after LY294002 treatment at the 48 hr time point.D: The
number colonies of anchorage independentgrowth formedby PC-3 cells overexpressing eachOPN-SI as compared to empty vector control
cellswas analyzedin thepresenceor absenceofLY294002 inhibitor.$P < 0.002.
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by inducing cell proliferation. In vitro, although
OPNb overexpressing cells promoted an increase at
proliferation rates, the results were not significant.
These controversial findings indicate that the role of
OPNb on activating tumor growth and cell prolifera-
tion in vivo could be potentially mediated by paracrine
signals secreted by the tumor microenvironment, as
has been intensely investigated [19,20]. It remains to
be determined whether OPNb acts independently or
in concert with OPNc to activate signaling pathways
that promote PCa progression.
In serum starvation conditions, we showed that
cell overexpressing OPNc, and to a lesser extent
OPNb, still enhanced PC-3 proliferation. These data
indicated that OPN-SI can promote tumor progres-
sion in a manner that is independent of growth fac-
tors, a typical feature of oncogenic gene products [17].
The data presented here provide evidence that cells
overexpressing OPNc and OPNb have enhanced cell
proliferation due to the promotion of cell survival by
these isoforms. First, cells overexpressing OPNc and
OPNb stimulated PI3K pro-survival signaling, which
could be one of the molecular mechanisms of activat-
ing pathways activating cell proliferation and/or res-
cuing cells from apoptotic stimuli, such as serum
starvation [18,21]. Second, PC-3 cells overexpressing
OPNc had decreased proliferation and were induced
to die, when treated with an anti-OPNc antibody.
Finally, cells overexpressing OPNc and OPNb treated
with LY294002 had improved survival, overcoming
apoptosis typically induced by this drug treatment.
Previous reports found that total OPN is able to pre-
vent cell death in response to diverse stress stimuli,
including serum starvation and also inhibit apoptosis
in several systems [21], but no reports have described
previously the individual role of each OPN-SI. Based
on published reports and our present results, we
propose that OPNc and OPNb splicing isoforms may
enhance PC-3 survival due to enhanced cell prolifera-
tion. Further studies should be carried out to deter-
mine the cellular and mechanisms able to stimulate
cell growth evoked by OPNb and OPNc overexpres-
sion and whether apoptosis or other mechanisms of
cell death inhibition are also involved in mediating
the survival roles for OPNc and OPNb in PCa.
Besides promoting higher proliferating rates in PC-3
tumor cells, we have also showed that secreted OPNc
also stimulates RWPE-1 (a normal prostate epithelia
cell line) proliferation. Therefore, these data indicated
that OPNc is not only involved in PCa progression
and survival, but may also contribute to early steps of
PCa tumorigenesis. OPNb, on the other hand, appears
to exert its main effects on cell proliferation at later
stages of tumor progression. Our data also demon-
strated that OPNc and OPNb stimulated PC-3 cell
motility and invasion and soft agar colony formation,
inferring the roles of these isoforms on metastatic
potential. Corroborating to these observations, cells
overexpressing OPNc and OPNb isoforms significantly
activated in vitro and in vivo the expression of MMP-
2, MMP-9, and VEGF, molecules critical to PCa
invasion and metastatic potential [22]. Some reports
detailed the signaling pathways mediating each one
of the OPN-SI roles. For instance, in hepatocarcinoma
cell lines, OPN-SI differentially activated migration-
associated signaling pathways. OPNa and OPNb,
but not OPNc, increased the expression of urokinase
type plasminogen activator and the phosphorylation
of p42/p44 MAP kinase [11]. These same isoforms
promoted pancreatic and fibrosarcoma tumors mainly
by protecting cells against stress-induced apoptosis,
by inducing NF-kappaB activation and FAK phos-
phorylation [13]. Our group recently demonstrated
that OPNc activated ovarian tumor progression fea-
tures by inducing the PI3K signaling pathway [8]. The
present work adds a mechanistic understanding of
the roles of OPN-SI in tumor progression by demon-
strating that both OPNc and OPNb can activate dis-
tinct aspects of PCa progression through activation of
PI3K signaling. Hence, specific knowledge of which
signaling pathway and specific OPN-SI are mediating
tumor progression opens possibilities to apply anti-
splicing isoforms strategies in addition to signaling
pathways inhibitors as therapeutic approaches to
inhibit tumor progression [12,23]. Therefore, we
propose that OPNc and OPNb-mediated roles on acti-
vating PCa progression features may be linked to the
activation of PI3K signaling to promote PCa progres-
sion in both localized and advanced PCa. In support
of our findings, previous studies have demonstrated
that treatment of PCa cells with LY294002 resulted in
cell cycle-mediated arrest, induction of apoptosis
and inhibition on cellular invasion [24,25]. Although
LY294002 can inhibit other gene products [26], in our
study, PC-3 proliferation and migration capacity
were specifically inhibited in OPNc and OPNb over-
expressing cells, indicating that at least the effect on
these cell features are mainly mediated by PI3K
signaling and upstream signals activated by these
splicing isoforms. However, cells overexpressing
OPNc and OPNb overcame soft agar colony forma-
tion inhibition, indicating that these OPN-SI could be
inducing PI3K signaling, which is classically involved
on mediating soft colony formation, cell survival and
anoikis, as described [24–26]. Moreover, PI3K/Akt
signals have been reported to directly involve the
upregulation of MMP-2 and MMP-9 [22,27]. There-
fore, it would appear from the present data, that the
OPNc and OPNb-mediated signals could possibly op-
erate through a cell receptor/PI3K/Akt/MMP-2/-9
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pathway. Further experiments will focus on verifying
which specific receptor and downstream signals are
being activated by OPNc and OPNb to modulate
PI3K signaling and promote PCa progression.
CONCLUSIONS
We provide strong evidence that overexpression of
OPNc and OPNb splice variants may be involved in
distinct steps of PCa progression. Additionally, we
demonstrated that the secreted forms of these OPN-SI
are mainly mediating OPN effects on tumor progression
by activating at least the PI3K pro-survival pathway.
Therefore, a better understanding of the molecular
mechanisms by which OPNc and OPNb activate PI3K
signaling and its main targets will open up possibili-
ties for developing improved PCa therapeutic
approaches that specifically downregulate these iso-
forms and their effects, inhibiting PCa progression.
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